Dental Associate Buy-In: How Equity Deal Structures Actually Work
Most associate buy-ins sell a 20% to 49% stake in the first tranche, with a path to 50/50 or full succession written into the agreement. The structure matters more than the headline percentage. Here's how the pieces usually fit.
Valuation basis
Two common methods: a percentage of collections (60% to 80% for a general practice) or an EBITDA multiple (4x to 6x for most GP practices, after normalizing owner compensation). On a $1.2M-collections practice with $300K of true EBITDA, those methods land in a similar zone: roughly $850K to $1M enterprise value. If the seller's number assumes add-backs, verify them the same way a DSO would; our EBITDA margin benchmark covers what counts and what doesn't.
Tranche size and funding
A 30% tranche on a $900K valuation is $270K. Associates rarely write that check. Typical funding: a practice-acquisition bank loan over 7 to 10 years at 7% to 9%, or a seller note over 5 to 7 years at similar rates. On $270K at 8% over 7 years, that's about $4,200 a month. The distribution stream has to cover it: 30% of $300K in profit is $90K a year, or $7,500 a month, so the deal cash-flows with room to spare. If it doesn't, the valuation is too high or the tranche is too big.
Seller notes shift risk in ways both sides should price in - standby provisions, offset rights, default triggers. The mechanics are the same as in a full sale; see seller financing terms.
Income after the buy-in
The standard split: the associate keeps production-based compensation (usually 30% to 33% of personal collections) and adds profit distributions matching their ownership share. Get the order of operations in writing - owner comp comes out before profit is calculated, or the junior partner quietly subsidizes the senior's clinical days.
The clauses that cause disputes
Buy-sell terms (what happens on death, disability, or exit, and at what valuation formula), decision rights on spending and hiring above a dollar threshold, non-compete scope, and the trigger and pricing for the next tranche. Most buy-in fights are about a clause nobody negotiated, not the price.
Before signing anything, run the same diligence you'd run buying the whole practice: chart counts, payer mix, staff tenure, lease terms. The full list is in our acquisition due diligence checklist. A buy-in is a practice purchase in slow motion, and it deserves the same scrutiny.
